[Table/Fig-5]:
Comparison Between Patients with or without Adverse Outcomes on Follow-Up
| Baseline Characteristic | Adverse Event | No Adverse Event | p-value |
|---|---|---|---|
| Age (in years) | 57.6±10.8 | 57.3±18.2 | 0.95 |
| % of males | 52.9 | 57.1 | 0.78 |
| Duration of hospital stay (days) | 5.9±2.9 | 5.6±3.1 | 0.74 |
| Diabetes Mellitus (%) | 52.9 | 34.3 | 0.19 |
| Hypertension (%) | 35.3 | 37.1 | 0.89 |
| Body mass index (kg/m2) | 23.3±2.4 | 23.1±2.6 | 0.79 |
| Blood Glucose (mg/dl) | 169.4±117.8 | 162.9±132.8 | 0.86 |
| Hemoglobin (gm/dl) | 11.9±2.4 | 12.8±2.9 | 0.27 |
| Total blood count (per cumm) | 11741±6285 | 9868±3189 | 0.15 |
| Serum Creatinine (mg/dl) | 1.3±0.4 | 1.2±0.4 | 0.615 |
| Uric Acid (mg/dl) | 8.8±3.9 | 7.8±2.8 | 0.295 |
| Sodium (mEq/L) | 132.7±7.1 | 134.3±4.8 | 0.341 |
| Admission NT-proBNP (pg/ml) | 14800.4±11637.4 | 7957.6±9092.9 | 0.0245 |
| 48hour NT-proBNP (pg/ml) | 15547.7±12348.2 | 4950.0±7580.1 | 0.0004 |
| Group 1 (%) | 76.5 | 11.4 | <0.0001 |
| Group 2 (%) | 23.5 | 88.6 | <0.0001 |
| hsTropT (ng/ml) | 0.25±0.47 | 0.23±0.6 | 0.905 |
| hsCRP (mg/dl) | 2.2±1.9 | 2.0±1.7 | 0.703 |
| LVIDd (mm) | 5.4±0.9 | 5.6±0.9 | 0.456 |
| LVIDs (mm) | 4.3±1.0 | 4.5±1.1 | 0.529 |
| EF (%) | 36.9±9.9 | 37.6±9.5 | 0.807 |
| Follow-up duration (in days) | 96.9±67.8 | 136.8±34.3 | 0.007 |
(CRP=C-reactive protein; EF=Left ventricular ejection fraction; Groups 1 and 2=Groups with rising or declining NT-proBNP levels respectively after admission; hs=high sensit ivity; LVID= Left ventricular internal dimension in d (diastole) or s (systole); NT-proBNP=N-terminal pro B-type natriuretic peptide; TropT=cardiac Troponin T)